1. Spaide RF, Campeas L, Haas A, Yannuzzi LA, Fisher YL, Guyer DR, et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology. 1996; 103:2070–2079.
Article
2. Von Graefe A. Ueber centrale recidivierende retinitis. Graefes Arch Clin Exp Ophthalmol. 1866; 12:211–215.
3. Maumenee A. Clinical manifestations (Symposium: macular diseases). Trans Am Acad Ophthalmol Otolaryngol. 1965; 69:605–613.
4. Donald J, Gass M. Pathogenesis of disciform detachment of the neuroepithelium: II. Idiopathic central serous choroidopathy. Am J Ophthalmol. 1967; 63:587/15–615/43.
5. Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology. 2008; 115:169–173.
Article
6. Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S. Group CSCCCS. Risk factors for central serous chorioretinopathy: a case–control study. Ophthalmology. 2004; 111:244–249.
7. Chan WM, Lai TY, Tano Y, Liu DT, Li KK, Lam DS. Photodynamic therapy in macular diseases of Asian populations: when East meets West. Jpn J Ophthalmol. 2006; 50:161–169.
Article
8. Balo K, Mihluedo H. [Idiopathic central serous chorioretinopathy: two case reports observed in Togo]. Med Trop (Mars). 1996; 56:381–383.
9. Desai UR, Alhalel AA, Campen TJ, Schiffman RM, Edwards PA, Jacobsen GR. Central serous chorioretinopathy in African Americans. J Natl Med Assoc. 2003; 95:553–559.
10. Liu B, Deng T, Zhang J. RISK FACTORS FOR CENTRAL SEROUS CHORIORETINOPATHY: A Systematic Review and Meta-Analysis. Retina. 2016; 36:9–19.
11. Carvalho-Recchia CA, Yannuzzi LA, Negrao S, Spaide RF, Freund KB, Rodriguez-Coleman H, et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology. 2002; 109:1834–1837.
Article
12. Khairallah M, Kahloun R, Tugal-Tutkun I. Central serous chorioretinopathy, corticosteroids, and uveitis. Ocul Immunol Inflamm. 2012; 20:76–85.
Article
13. Chung H, Kim KH, Kim JG, Lee SY, Yoon YH. Retinal complications in patients with solid organ or bone marrow transplantations. Transplantation. 2007; 83:694–699.
Article
14. Mayo GL, Tolentino MJ. Images in clinical medicine. Central serous chorioretinopathy in pregnancy. N Engl J Med. 2005; 353:e6.
15. Yannuzzi LA. Type A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc. 1986; 84:799.
Article
16. Tittl MK, Spaide RF, Wong D, Pilotto E, Yannuzzi LA, Fisher YL, et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol. 1999; 128:63–68.
Article
17. Mansuetta CC, Mason JO, Swanner J, Feist RM, White MF, Thomley ML, et al. An association between central serous chorioretinopathy and gastroesophageal reflux disease. Am J Ophthalmol. 2004; 137:1096–1100.
Article
18. Cotticelli L, Borrelli M, d'Alessio A, Menzione M, Villani A, Piccolo G, et al. Central serous chorioretinopathy and Helicobacter pylori. Eur J Ophthalmol. 2006; 16:274–278.
Article
19. Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, et al. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015; 48:82–118.
Article
20. Ross A, Ross AH, Mohamed Q. Review and update of central serous chorioretinopathy. Curr Opin Ophthalmol. 2011; 22:166–173.
Article
21. Framme C, Walter A, Gabler B, Roider J, Sachs HG, Gabel VP. Fundus autofluorescence in acute and chronic-recurrent central serous chorioretinopathy. Acta Ophthalmol Scand. 2005; 83:161–167.
Article
22. Imamura Y, Fujiwara T, Margolis R, Spaide RF. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina. 2009; 29:1469–1473.
Article
23. Montero J, Ruiz-Moreno J. Optical coherence tomography characterisation of idiopathic central serous chorioretinopathy. Br J Ophthalmol. 2005; 89:562–564.
Article
24. Yoshioka H, Katsume Y, Akune H. Experimental Central Serous Chorioretinopathy in Monkey Eyes: Fluorescein Angiographic Findings. Ophthalmologica. 1982; 185:168–178.
Article
25. Sakaue M, Hoffman BB. Glucocorticoids induce transcription and expression of the alpha 1B adrenergic receptor gene in DTT1 MF-2 smooth muscle cells. J Clin Invest. 1991; 88:385.
Article
26. Caccavale A, Romanazzi F, Imparato M, Negri A, Morano A, Ferentini F. Central serous chorioretinopathy: a pathogenetic model. Clin Ophthalmol. 2011; 5:239.
Article
27. Verma L, Purohit A, Tewari H, Biswas N, Talwar D, Jhingan S, et al. A study of endogenous cortisol profile in patients with central serous retinopathy with single and multiple leaks. Indian J Pharmacol. 2001; 33:96–99.
28. Gilbert CM, Owens SL, Smith PD, Fine SL. Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol. 1984; 68:815–820.
Article
29. Yannuzzi LA, Shakin JL, Fisher YL, Altomonte MA. Peripheral retinal detachments and retinal pigment epithelial atrophic tracts secondary to central serous pigment epitheliopathy. Ophthalmology. 1984; 91:1554–1572.
Article
30. Jalkh AE, Jabbour N, Avila MP, Trempe CL, Schepens CL. Retinal pigment epithelium decompensation. I. Clinical features and natural course. Ophthalmology. 1984; 91:1544–1548.
31. Iida T, Yannuzzi LA, Spaide RF, Borodoker N, Carvalho CA, Negrao S. Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina. 2003; 23:1–7. quiz 137-8.
Article
32. Gäckle HC, Lang GE, Freißler KA, Lang GK. Clinical, fluorescein angiographic and demographic aspects in central serous chorioretinopathy. Ophthalmologe. 1998; 95:529–533.
Article
33. Yamada K, Hayasaka S, Setogawa T. Fluorescein-angiographic patterns in patients with central serous chorioretinopathy at the initial visit. Ophthalmologica. 1992; 205:69–76.
Article
34. Burumcek E, Mudun A, Karacorlu S, Arslan MO. Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up. Ophthalmology. 1997; 104:616–622.
Article
35. Prünte C. Indocyanine green angiographic findings in central serous chorioretinopathy. Int Ophthalmol. 1995; 19:77–82.
Article
36. Iida T, Kishi S, Hagimura N, Shimizu K. Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy. Retina. 1999; 19:508–512.
Article
37. Spaide RF. Enhanced depth imaging optical coherence tomography of retinal pigment epithelial detachment in age-related macular degeneration. Am J Ophthalmol. 2009; 147:644–652.
Article
38. Hirata M, Tsujikawa A, Matsumoto A, Hangai M, Ooto S, Yamashiro K, et al. Macular choroidal thickness and volume in normal subjects measured by swept-source optical coherence tomography. Invest Ophthalmol Vis Sci. 2011; 52:4971–4978.
Article
39. Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol. 2013; 58:103–126.
Article
40. Song IS, Shin YU, Lee BR. Time-periodic characteristics in the morphology of idiopathic central serous chorioretinopathy evaluated by volume scan using spectral-domain optical coherence tomography. Am J Ophthalmol. 2012; 154:366–375.
Article
41. Maruko I, Iida T, Sugano Y, Ojima A, Sekiryu T. Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy. Retina. 2011; 31:1603–1608.
Article
42. Eandi CM, Ober M, Iranmanesh R, Peiretti E, Yannuzzi LA. Acute central serous chorioretinopathy and fundus autofluorescence. Retina. 2005; 25:989–993.
Article
43. Lee WJ, Lee JH, Lee BR. Fundus autofluorescence imaging patterns in central serous chorioretinopathy according to chronicity. Eye (Lond). 2016; 30:1336–1342.
Article
44. Yannuzzi LA. Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol. 2010; 149:361–363.e1.
Article
45. Sharma T, Shah N, Rao M, Gopal L, Shanmugam MP, Gopalakrishnan M, et al. Visual outcome after discontinuation of corticosteroids in atypical severe central serous chorioretinopathy. Ophthalmology. 2004; 111:1708–1714.
Article
46. Leaver P, Williams C. Argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol. 1979; 63:674–677.
Article
47. Robertson DM. Argon laser photocoagulation treatment in central serous chorioretinopathy. Ophthalmology. 1986; 93:972–974.
Article
48. Gilbert CM, Owens SL, Smith PD, Fine SL. Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol. 1984; 68:815–820.
Article
49. Salehi M, Wenick AS, Law HA, Evans JR, Gehlbach P. Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev. 2015; CD011841.
Article
50. Taban M, Boyer DS, Thomas EL, Taban M. Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol. 2004; 137:1073–1080.
Article
51. Lim JW, Kang SW, Kim Y-T, Chung SE, Lee SW. Comparative study of patients with central serous chorioretinopathy undergoing focal laser photocoagulation or photodynamic therapy. Br J Ophthalmol. 2011; 95:514–517. DOI:
bjo.2010.182121.
Article
52. Inoue R, Sawa M, Tsujikawa M, Gomi F. Association between the efficacy of photodynamic therapy and indocyanine green angiography findings for central serous chorioretinopathy. Am J Ophthalmol. 2010; 149:441–446.e2.
Article
53. Shin JY, Woo SJ, Yu HG, Park KH. Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2011; 31:119–126.
Article
54. Reibaldi M, Cardascia N, Longo A, Furino C, Avitabile T, Faro S, et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol. 2010; 149:307–315.e2.
Article
55. Nicoló M, Eandi CM, Alovisi C, Grignolo FM, Traverso CE, Musetti D, et al. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol. 2014; 157:1033–1037.e2.
Article
56. Alkin Z, Ozkaya A, Agca A, Yazici AT, Demirok A. Early visual and morphologic changes after half-fluence photodynamic therapy in chronic central serous chorioretinopathy. J Ocul Pharmacol Ther. 2014; 30:359–365.
Article
57. Roisman L, Magalhães FP, Lavinsky D, Moraes N, Hirai FE, Cardillo JA, et al. Micropulse diode laser treatment for chronic central serous chorioretinopathy: a randomized pilot trial. Ophthalmic Surg Lasers Imaging Retina. 2013; 44:465–470.
Article
58. Lim SJ, Roh MI, Kwon OW. Intravitreal bevacizumab injection for central serous chorioretinopathy. Retina. 2010; 30:100–106.
Article
59. Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Curr Eye Res. 2010; 35:91–98.
Article
60. Seong HK, Bae JH, Kim ES, Han JR, Nam WH, Kim HK. Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short-term effect. Ophthalmologica. 2009; 223:343–347.
Article
61. Lee ST, Adelman RA. The Treatment of Recurrent Central Serous Chorioretinopathy with Intravitreal Bevacizumab. J Ocul Pharmacol Ther. 2011; 27:611–614.
Article
62. Bae SH, Heo JW, Kim C, Kim TW, Lee JY, Song SJ, et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol. 2011; 152:784–792.e2.
Article
63. Meyerle CB, Freund KB, Bhatnagar P, Shah V, Yannuzzi LA. Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina. 2007; 27:943–946.
Article
64. Tatham A, Macfarlane A. The use of propranolol to treat central serous chorioretinopathy: an evaluation by serial OCT. J Ocul Pharmacol Ther. 2006; 22:145–149.
Article
65. Pikkel J, Beiran I, Ophir A, Miller B. Acetazolamide for central serous retinopathy. Ophthalmology. 2002; 109:1723–1725.
Article